FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia

View source ↗

Summary

FDA approves Auvelity as the first non-antipsychotic drug to treat agitation associated with dementia due to Alzheimer’s disease in adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AUVELITY (Dextromethorphan hydrobromide, bupropion hydrochloride)

Snippet

The U.S. Food and Drug Administration today approved an expanded use for Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat agitation associated with dementia due to Alzheimer’s disease in adults.